Close Menu

Share with your friends

Close

Actinogen Medical (ASX: ACW)

With an estimated 50 million sufferers of Alzheimer’s Disease around the world, healthcare costs are spiralling out of control, so much so that the addressable market will be worth in excess of US$1TN by 2018.

The challenge for pharmaceutical companies such as Actinogen Medical (ASX:ACW) is not only to find a cure, but to affect change in what is to become a mega market.

To do so, ACW is developing an Alzheimer’s treatment known as Xanamem™ that could potentially identify an underlying common denominator of dementia sufferers, and prove to be a significant new treatment for Alzheimer’s disease.

ACW’s Phase II Xanamem™ trials could be the catalyst for raising ACW’s value, with the hope that the company follows in the footsteps of its peers such as Avanir Pharmaceuticals which was bought by Otsuka of Japan for $3.5BN.

The information in this page should not be the only trigger for your investment decision. Click on the links below for a more in-depth and informed examination of the company. We strongly recommend you seek professional financial advice whenever making financial investment decisions.

With its Phase II trials underway and tracking well, ACW could put itself in a strong position to not only change the treatment for Alzheimer’s Disease, have a positive effect on the growing market and also attract big pharma interest.

If it is able to do so, this $36.4 million capped biotech, could be in for some serious investor attention.

 

Latest Article

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

[gravityform id="9" name="OM Popup NEW" title="false" description="false" ajax="true"]
  • This field is for validation purposes and should be left unchanged.
[gravityform id="9" name="OM Popup NEW" title="false" description="false" ajax="true"]
  • This field is for validation purposes and should be left unchanged.